We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

55 hedge funds and large institutions have $265M invested in Aspire Biopharma in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

2% more capital invested

Capital invested by funds: $260M → $265M (+$5.14M)

0% less ownership

Funds ownership: 0.07% → 0.07% (-0%)

7% less funds holding

Funds holding: 59 → 55 (-4)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
55
Holders Change
-4
Holders Change %
-6.78%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
9
Reduced
8
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
Radcliffe Capital Management
Pennsylvania
+$3.47M
2
LP
LMR Partners
United Kingdom
+$2.55M
3
AC
Aristeia Capital
Connecticut
+$1.85M
4
GCL
Glazer Capital LLC
New York
+$1.15M
5
WAM
Wolverine Asset Management
Illinois
+$894K

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$6.79M
2
UOC
UBS O'Connor
Illinois
-$2.33M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$1.44M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$563K
5
CH
CVI Holdings
Delaware
-$507K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
26
Aristeia Capital
Connecticut
$3.15M +$1.85M +151 +145%
SCM
27
Shaolin Capital Management
Florida
$3.09M +$514K +42 +20%
Nomura Holdings
28
Nomura Holdings
Japan
$3.09M – – –
WA
29
Whitebox Advisors
Minnesota
$2.58M – – –
LP
30
LMR Partners
United Kingdom
$2.58M +$2.55M +208 New
Hudson Bay Capital Management
31
Hudson Bay Capital Management
Connecticut
$2.06M – – –
KL
32
KIM LLC
Kansas
$2.06M – – –
WAM
33
Weiss Asset Management
Massachusetts
$2.06M – – –
WP
34
Woodline Partners
California
$2.06M – – –
PAMP
35
Polar Asset Management Partners
Ontario, Canada
$1.81M – – –
PMAM
36
Picton Mahoney Asset Management
Ontario, Canada
$1.55M – – –
CCM
37
CAAS Capital Management
New York
$1.54M – – –
CSS
38
Cubist Systematic Strategies
Connecticut
$1.24M -$24.5K -2 -2%
Citigroup
39
Citigroup
New York
$1.03M -$282K -23 -21%
ACM
40
Atalaya Capital Management
New York
$1.03M – – –
CCM
41
Context Capital Management
California
$1.03M – – –
OCM
42
Oaktree Capital Management
California
$1.03M – – –
KKRC
43
Kohlberg Kravis Roberts & Co
New York
$773K – – –
Bank of Montreal
44
Bank of Montreal
Ontario, Canada
$733K -$563K -46 -44%
WCMNY
45
Westchester Capital Management (New York)
New York
$582K +$576K +47 New
OAC
46
OMERS Administration Corp
Ontario, Canada
$516K +$514K +42 New
MTCM
47
Mint Tower Capital Management
Netherlands
$515K – – –
AC
48
Athos Capital
Hong Kong
$515K +$514K +42 New
DAM
49
DLD Asset Management
New York
$480K +$36.7K +3 +8%
CM
50
Cohanzick Management
New York
$377K – – –
1
2
3

ASBP Hedge Fund Activity: Q4 2022 in Review

55 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q4 2022, worth a combined $265M — up 2% from $260M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ASBP and 4 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 9 added.

The largest buyer was Radcliffe Capital Management, adding an estimated $3.47M. The largest seller was Highbridge Capital Management, cutting an estimated $6.79M.

  • 55 institutional investors held Aspire Biopharma (ASBP) as of Q4 2022, down from 59 in Q3 2022.
  • Funds reported $265M of Aspire Biopharma stock for Q4 2022, up 2% quarter-over-quarter.
  • 4 funds opened new Aspire Biopharma positions in Q4 2022 and 8 closed out, a net change of -4 holders.
  • The largest Aspire Biopharma buyer in Q4 2022 was Radcliffe Capital Management, an estimated $3.47M added.
  • The largest Aspire Biopharma seller in Q4 2022 was Highbridge Capital Management, an estimated $6.79M sold.

Based on aggregated 13F filings for Q4 2022.